

## BSW Formulary Update – Following APC August 2021 meeting

### New and Updated Prescribing Guidelines/Shared care Guideline

- **NEW** – [BSW SCA - Topical Testosterone for low libido in menopause in adult women on HRT \(off-label indication\)](#)
  - The TLS for testosterone for low libido in adult women on HRT has changed from RED to **AmbWSCA**. This indication is off-label but recognised as an option in the NICE guidance for menopause [NG23](#).
  - This new BSW SCA details standards and expectations agreed locally if a GP is asked by NHS clinicians to take on the prescribing of testosterone for low libido in adult women on HRT. It provides information on correct usage of products (Testogel® sachets or Tostran® multi-dose pump); desired product should be chosen by the Specialist.
  - If a patient elects to access private menopausal services and is offered topical testosterone, in line with the [Medicines Management Advisory Summary for Private Treatments](#), the entire 'episode of care', including ongoing prescribing should remain with the private provider. If there are circumstances in which the GP agrees to take on prescribing that has been initiated privately, we would expect the private provider to follow the standards of the Specialist as detailed in our SCA.
  - There is no obligation for the GP to provide the recommended treatment if the GP does not feel clinically competent to do this and it is contrary to his/her normal clinical practice.
- **Updated** – [BSW SCA Somatropin for the treatment of growth hormone deficiency in adults](#) This was originally a SCA for patients seen at the RUH that has been updated and now includes GWH and SFT.

### New additions to the BSWformulary

- [Benzbromarone tablets](#) (Unlicensed) Included as third line option for gout for patients with intolerance or contra-indications to other agents. Specialist retains prescribing **RED TLS**

### Other BSWformulary website updates

- [Trimbow® MDI triple therapy \(ICS/LAMA/LABA\)](#). Asthma indication (*For the treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year*) added to existing formulary entry.
- [Cavilon barrier cream 28g and 90g and Cavilon No sting barrier film 1ml](#) **GREEN TLS** These Cavilon preparations are not listed on the [BSW MOCH Barrier Cream Guidance](#) but are included in the formulary due to differences in existing treatment pathways barrier creams (prior to merger of BSWCCGs) that have yet to be aligned.
- The APC has recently turned down applications for prasterone 6.5mg pessaries ([Intrarosa®](#)) and estriol vaginal gel 50microgram/g ([Blisse®](#)). These should not be prescribed on the NHS in BSW.
- [Varenicline tablets \(Champix\)](#) moved to non-formulary due to ongoing supply issues.
- A link has been added to the [front page of Netformulary](#) for a new resource provided by the Specialist Pharmacy Service which summarises advice on drug monitoring [Drug Monitoring – SPS - Specialist Pharmacy Service](#)
- [BSW Covid guidelines](#) These BSW documents are reviewed regularly to ensure content is up to date and correct. Please also see [COVID-19 Medicines Optimisation – Specialist Pharmacy Service](#) for further resources and tools to support Medicines Optimisation activities during the COVID-19 pandemic.

### What the BSW CCG formulary team are currently working on

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSWformulary across primary and secondary care. Reviewing formulary position of Cox-2 inhibitors.
- Working with AWP on an oral antipsychotic SCA.
- Reviewing the national SCA consultations by RMOC.
- Updating the HRT pathway.
- Reviewing policy on use of Continuous Glucose Monitoring (CGM).
- Updating the BSW primary care antibiotic guidance in line with NICE updates [including our local primary care pathway for prescribing in acne] and reviewing TLS and primary care prescribing of rifampicin.
- Reviewing COPD guidance.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswccg.formulary@nhs.net](mailto:bswccg.formulary@nhs.net)